Publications (490)1658.03 Total impact
-
Article: C4.4A Expression Is Associated with a Poor Prognosis of Esophageal Squamous Cell Carcinoma.
Annals of Surgical Oncology 01/2013; · 4.17 Impact Factor -
Article: [Lymph node micrometastases in colorectal cancer].
[show abstract] [hide abstract]
ABSTRACT: Lymph node (LN) micrometastases in colorectal cancer (CRC) has been discussed for a long time. Previous reports showed that micrometastases detected by immunohistochemistry (IHC) appeared to have no clinical impact, but that occult disease detected by molecular techniques such as RT-PCR might be associated with poor prognosis. At present, several factors are proposed as high risks for disease recurrence of stage II CRC, including T4 invasiveness, vascular invasion, poorly differentiated adenocarcinoma or mucinous carcinoma, tumor budding, wall perforation, and insufficient assessment of dissected LNs. However, it was reported that 75% of 24,847 stage II CRC patients retained specific risk factors, and the efficacy of chemotherapy in such patients has not been confirmed. A recent meta-analysis by Weitz et al. has concluded that occult disease was significantly associated with poor prognosis of node-negative CRC, irrespective of the detection method, i.e., IHC or RT-PCR. For efficient selection of high-risk stage II CRC patients, a prospective, large-scale clinical trial is essential using a convenient, simple molecular modality such as the one-step nucleic acid amplification assay.Nippon Geka Gakkai zasshi 01/2013; 114(1):17-21. -
Article: Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: effect on growth retardation of established colon tumor.
[show abstract] [hide abstract]
ABSTRACT: In continuing search for effective treatments of cancer, the emerging model aims at efficient intracellular delivery of therapeutics into tumor cells in order to increase the drug concentration. However, the implementation of this strategy suffers from inefficient cellular uptake and drug resistance. Therefore, pH-sensitive nanosystems have recently been developed to target slightly acidic extracellular pH environment of solid tumors. The pH targeting approach is regarded as a more general strategy than conventional specific tumor cell surface targeting approaches, because the acidic tumor microclimate is most common in solid tumors. When nanosystems are combined with triggered release mechanisms in endosomal or lysosomal acidic pH along with endosomolytic capability, the nanocarriers demonstrated to overcome multidrug resistance of various tumors. Here, novel pH sensitive carbonate apatite has been fabricated to efficiently deliver anticancer drug Doxorubicin (DOX) to cancer cells, by virtue of its pH sensitivity being quite unstable under an acidic condition in endosomes and the desirable size of the resulting apatite-DOX for efficient cellular uptake as revealed by scanning electron microscopy. Florescence microscopy and flow cytometry analyses demonstrated significant uptake of drug (92%) when complexed with apatite nanoparticles. In vitro chemosensitivity assay revealed that apatite-DOX nanoparticles executed high cytotoxicity in several human cancer cell lines compared to free drugs and consequently apatite-DOX-facilitated enhanced tumor inhibitory effect was observed in colorectal tumor model within BALB/cA nude mice, thereby shedding light on their potential applications in cancer therapy.PLoS ONE 01/2013; 8(4):e60428. · 4.09 Impact Factor -
Article: Advanced gastric cancer deriving from submucosal heterotopic gastric glands based on pathological diagnosis.
Nippon Shokakibyo Gakkai zasshi The Japanese journal of gastro-enterology 01/2013; 110(2):290-3. -
Article: Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma.
[show abstract] [hide abstract]
ABSTRACT: The functions of many long non-coding RNAs (ncRNAs) in human cancers have not yet been elucidated. The long ncRNA HOTAIR is expressed from the developmental HOXC locus located on chromosome 12q13.13. Previous reports have demonstrated that HOTAIR associates with chromatin modifications in cooperation with the Polycomb complex PRC2, and promotes breast and colorectal cancer metastasis. In this study, we examined the clinical significance of HOTAIR expression in patients with hepatocellular carcinoma (HCC). HOTAIR expression was detected in primary HCCs in 13 out of 64 patients. Patients with HOTAIR expression had significantly poorer prognoses and a larger primary tumor size than those without HOTAIR expression, similar to studies in breast and colorectal cancers. Moreover, introduction of human HOTAIR into liver cancer cells revealed that HOTAIR promoted more rapid proliferation compared to control cells. Thus, although the clinical significance of HOTAIR expression in HCC may not be as pronounced as that in breast and colorectal cancers, the current study demonstrates that HOTAIR expression is associated with HCC progression, warranting further studies.Oncology Reports 12/2012; · 1.84 Impact Factor -
Article: Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer.
[show abstract] [hide abstract]
ABSTRACT: We previously studied hypoxic tumor cells from hepatic metastases of colorectal cancer (CRC) and determined several potential prognostic factors, including expression of ephrin-A1 (EFNA1), which was highly induced by hypoxia. Here, we further evaluated the prognostic impact of EFNA1 expression. Samples from a total of 366 CRC patients from 11 institutes were analyzed by either microarray (n=220) or quantitative reverse-transcriptase polymerase chain reaction (n=146). EFNA1 was an independent prognostic factor for CRC (p<0.05). In vitro assays revealed that loss of EFNA1 following siRNA treatment was associated with reduced proliferative activity and decreased invasion and migration of CRC cell lines. EFNA1 expression is a useful marker for predicting high risk of relapse and cancer-related death in patients who have undergone curative resection for CRC.International Journal of Oncology 12/2012; · 2.40 Impact Factor -
Article: Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer.
[show abstract] [hide abstract]
ABSTRACT: Pancreatic cancer is one of the commonest causes of death from cancer. Despite the availability of various treatment modalities, such as surgery, chemotherapy, and radiotherapy, the 5-year survival remains poor. Although gemcitabine-based chemotherapy is typically offered as the standard care, most patients do not survive longer than 6 months. Therefore, new therapeutic approaches are needed. The α-gal epitope (Galα1-3Galβ1-4GlcNAc-R) is abundantly synthesized from glycoproteins and glycolipids in non-primate mammals and New World monkeys, but is absent in humans, apes and Old World monkeys. Instead, they produce anti-Gal antibody (Ab) (forming about 1% of circulating immunoglobulins), which specifically interacts with α-gal epitopes. Anti-Gal Ab can be exploited in cancer immunotherapy as vaccines that target antigen presenting cells (APC) to increase their immunogenicity. Tumor cells or tumor cell membranes from pancreatic cancer are processed to express α-gal epitopes. Subsequent vaccination with such processed cell membranes result in in vivo opsonization by anti-Gal IgG in cancer patients. The interaction of the Fc portion of the vaccine-bound anti-Gal with Fcγ receptors of APC induces effective uptake of the vaccinating tumor cell membranes by the APC, followed by effective transport of the vaccinating tumor membranes to the regional lymph nodes, and processing and presentation of the tumor-associated antigens (TAAs). Activation of tumor-specific B and T cells could elicit an immune response that in some patients is potent enough to eradicate the residual cancer cells that remain after completion of standard therapy. This review addresses these topics and new avenues of clinical importance related to this unique antigen/antibody system (α-gal epitope/anti-Gal Ab) and advances in immunotherapy in pancreatic cancer.Cancer Science 12/2012; · 3.33 Impact Factor -
Article: Larynx-Preserving Limited Resection and Free Jejunal Graft For Carcinoma of the Cervical Esophagus.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: There is no generally accepted treatment strategy for cervical cancer. The aim of this study was to evaluate the safety and efficacy of larynx-preserving limited resection with free jejunal graft for cervical esophageal cancer. METHODS: We retrospectively reviewed data of 58 patients with cervical esophageal cancer who underwent limited resection and free jejunal graft with or without laryngeal preservation. Among them, 45 patients received neoadjuvant treatment. RESULTS: Larynx-preserving surgery was conducted in 33 of the 58 patients (56.9 %). A higher proportion of patients who underwent laryngopharyngectomy with cervical esophagectomy (larynx-nonpreserving group) had cT4 tumors than those who underwent larynx-preserving cervical esophagectomy (larynx-preserving group) (72 vs. 12 %). The overall incidence of postoperative complications was similar in the two groups (56 vs. 52 %). The 5-year survival rate was 44.9 % for the entire group. Laryngeal preservation did not reduce overall survival compared with the larynx-nonpreserving operation (5-year survival rate: 57.8 vs. 25.8 %). Multivariate analysis identified the number of metastatic lymph nodes as the only independent prognostic factor. CONCLUSIONS: The present study demonstrated that larynx-preserving limited resection with free jejunal graft is feasible. Also, this approach did not worsen the prognosis compared with the larynx-nonpreserving operation. Limited resection with free jejunal graft and laryngeal preservation is a promising treatment strategy for cervical esophageal cancer.World Journal of Surgery 12/2012; · 2.36 Impact Factor -
Article: Distinct expression of C4.4A in colorectal cancer detected by different antibodies.
[show abstract] [hide abstract]
ABSTRACT: The metastasis-associated gene C4.4A encodes a glycolipid-anchored membrane protein expressed in several human malignancies. The present study aimed to perform a detailed assessment of C4.4A expression in colorectal cancer tissues, in terms of intra-cellular localization, intra-tumoral location and difference in molecular weight. To advance this goal, we developed three new antibodies against the C4.4A protein (two polyclonal Abs: C4.4A-119 and C4.4A-277 and one monoclonal Ab: C4.4A GPI-M) to use in addition to the two previously produced polyclonal Abs (C4.4A-81, C4.4A GPI-P). Antibody specificities were confirmed by absorption tests. Western blot analysis and immunohistochemistry showed that the C4.4A-119 and C4.4-277 Abs detected 70-kDa C4.4A, mainly in the cytoplasm, irrespective of intra-tumoral location. The C4.4A GPI-P and C4.4A GPI-M Abs reacted with the membranous ~40-kDa C4.4A, exclusively at the tumor invasive front, and each detected an identical tumor cell population. The tested antibodies showed varied C4.4A detection rates in 33 CRC tissues. The C4.4A-277 Ab yielded the highest positive rate in 29 of 33 CRC tissues (87.9%), while the C4.4A GPI-P and C4.4A GPI-M Abs each only showed 33.3% positivity. The present findings suggest that the GPI anchor signaling sequence may be essential for detecting membranous C4.4A at the invasive front of CRC tissues.International Journal of Oncology 11/2012; · 2.40 Impact Factor -
Article: SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers.
[show abstract] [hide abstract]
ABSTRACT: Findings from studies on stem cells have been applied to cancer stem cell (CSC) research, but little is known about the relationship between ES cell-related cell surface markers and CSCs. In this study, we focused on stage-specific embryonic antigen 3 (SSEA-3), a marker of mesenchymal stem cells and Muse cells in colorectal cancer (CRC). Expression of SSEA-3 in human CRC cell lines and clinical specimens, specifically the relationship of SSEA-3 expression and the representative CSC markers (CD44, CD166, ALDH, CD24 and CD26) as well as with mesenchymal stem cell/Muse cell marker (CD105) were assessed. To characterize SSEA-3-expressing cells, tumorigenicity, sphere formation ability, expression of iPS genes (Oct4, NANOG, SOX2 and c-Myc), cell proliferation and cell cycle status were assessed. SSEA-3 expression was identified in Caco-2, DLD-1, HT-29, SW480 and HCT116, but not in CaR-1 cells. No significant relationship between SSEA-3 and other stem cell markers was detected. SSEA-3+ cells showed increased tumorigenicity in vivo, but lower sphere formation ability in vitro than SSEA-3-. iPS gene expression was not correlated with SSEA-3 expression status. SSEA-3+ cells showed higher proliferative ability than SSEA-3- through enhanced cell cycles by decreased expression of p21Cip1/Waf1 and p27Kip1. Immunofluorescence analysis in clinical specimens indicated that expression of SSEA-3 is limited to stromal cells in normal mucosa but broad in poorly differentiated adenocarcinoma. These observations indicated that SSEA-3+ cells in CRC have immature phenotype but decreased self-renewal ability and may function as tumor transient amplifying cells or delayed contributing tumor-initiating cells.International Journal of Oncology 11/2012; · 2.40 Impact Factor -
Article: Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.
[show abstract] [hide abstract]
ABSTRACT: Mps one binder 1a (MOB1A) and MOB1B are key components of the Hippo signaling pathway and are mutated or inactivated in many human cancers. Here we show that intact Mob1a or Mob1b is essential for murine embryogenesis and that loss of the remaining WT Mob1 allele in Mob1aΔ/Δ1btr/+ or Mob1aΔ/+1btr/tr mice results in tumor development. Because most of these cancers resembled trichilemmal carcinomas, we generated double-mutant mice bearing tamoxifen-inducible, keratinocyte-specific homozygous-null mutations of Mob1a and Mob1b (kDKO mice). kDKO mice showed hyperplastic keratinocyte progenitors and defective keratinocyte terminal differentiation and soon died of malnutrition. kDKO keratinocytes exhibited hyperproliferation, apoptotic resistance, impaired contact inhibition, enhanced progenitor self renewal, and increased centrosomes. Examination of Hippo pathway signaling in kDKO keratinocytes revealed that loss of Mob1a/b altered the activities of the downstream Hippo mediators LATS and YAP1. Similarly, YAP1 was activated in some human trichilemmal carcinomas, and some of these also exhibited MOB1A/1B inactivation. Our results clearly demonstrate that MOB1A and MOB1B have overlapping functions in skin homeostasis, and exert their roles as tumor suppressors by regulating downstream elements of the Hippo pathway.The Journal of clinical investigation 11/2012; · 15.39 Impact Factor -
Article: Biological and clinical availability of adipose-derived stem cells for pelvic dead space repair.
[show abstract] [hide abstract]
ABSTRACT: Adipose-derived stem cells (ADSCs) are a very attractive cell source for regenerative and reconstructive medicine. Although ADSCs have already been used in cardiovascular disease and cosmetic surgery, they have not yet been used in gastroenterological surgery. In this study, we clarified the utility of the combined application of ADSCs and resected intraperitoneal fatty tissues as a sealant for the pelvic dead space that sometimes causes severe and fatal complications in colorectal and gynecological surgeries. In pelvic dead space model mice, mouse ADSCs efficiently maintained transplanted intraperitoneal fatty tissues without any incidence of adhesion to surrounding organs. In vivo and in vitro analyses revealed that transplanted ADSCs differentiated into endothelial cells by expressing the angiogenic factors vascular endothelial growth factor and hepatocyte growth factor. Mouse and human ADSCs contained a CD45(-)CD34(+) subset possessing high colony formation and sphere formation abilities. In addition, the CD45(-)CD34(+) subset consisted of two characteristic subsets: the CD34(+)CD90(+) angiogenic subset and the CD34(+)CD90(-) adipogenic subset. Grafts of human ADSCs with fat transplanted into mice were efficiently maintained for more than 12 months without volume reductions. A comparative study of graft maintenance efficacy between cultured human ADSCs and freshly isolated ADSCs indicated that the cultivation of ADSCs decreased their graft maintenance ability. These findings suggested that the angiogenic and adipogenic subsets act in coordination with each other and are essential for efficient graft maintenance.Stem cells translational medicine. 11/2012; 1(11):803-10. -
Article: [Surgical resection and s-1 administration for the treatment of hepatocellular carcinoma].
[show abstract] [hide abstract]
ABSTRACT: A 57-year-old man was admitted to our hospital for hepatocellular carcinoma (HCC). He underwent right hepatectomy with preoperative adjuvant transcatheter arterial chemoembolization. A follow-up computed tomography scan revealed a single pulmonary metastasis. After 2 courses of S-1 administration, he underwent left lower lobectomy, and a pathological specimen taken at the time was diagnosed as pulmonary metastasis of HCC. Although adjuvant chemotherapy with S-1 resulted in relapse-free survival for 2 years after pulmonary resection, he was found to have recurrence of liver cancer and underwent partial hepatectomy. This case report suggests that surgical resection and S-1 administration would be a useful treatment option for hepatocellular carcinoma with distant metastasis.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):1994-6. -
Article: [A case report of total remnant pancreatectomy for ductal carcinoma after distal pancreatectomy for invasive intraductal papillary mucinous carcinoma].
[show abstract] [hide abstract]
ABSTRACT: Recently, the number of case reports detailing cancer recurrence in the pancreatic remnants, following surgical resection of intraductal papillary-mucinous carcinoma (IPMC) of the pancreas has increased. We report the case of a 74-year-old woman who underwent pancreatic resection twice in a 3-year period for primary IPMC and remnant pancreatic ductal carcinoma. We first performed distal pancreatectomy for branched IPMC in the pancreatic tail. Histopathological examination revealed invasive IPMC and the negative margin of the pancreatic duct. The expression of tumor markers gradually increased in the 2 years and 4 months after the initial surgery, and a tumor was detected in the remnant pancreas. We performed total remnant pancreatectomy. The recurrent tumor consisted of moderately differentiated adenocarcinoma. Currently, the patient is alive without recurrence for a year since the second resection. This experience suggests that careful surveillance is necessary for IPMC.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):2140-2. -
Article: [An elderly patient with hepatocellular carcinoma-treatment by transcatheter arterial chemoembolization and subsequent laparoscopic hepatectomy].
[show abstract] [hide abstract]
ABSTRACT: An 81-year-old woman was followed-up for HCV-associated chronic hepatitis from 1995, and in 2005, a hepatocellular carcinoma(HCC) of approximately 4-cm diameter was detected in the left lateral segment of the liver. HCC was treated by transcatheter arterial-chemoembolization (TACE). In 2007 and 2009, we performed TACE 3 times for recurrent HCCs. After the last TACE, a recurrent lesion was present close to the treated lesion, and we performed laparoscopic left lateral segmentectomy in 2010, when the patient was 85 years old. She was discharged 12 days after the operation without any morbidity, and did not experience recurrent HCC for 2 years. Laparoscopic hepatectomy for HCC is an alternative radical and potentially less invasive approach for elderly persons.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):1828-30. -
Article: [A case of advanced hepatocellular carcinoma with inferior vena cava tumor thrombus and multiple intrahepatic metastases treated successfully by transcatheter arterial chemoembolization and radical hepatectomy].
[show abstract] [hide abstract]
ABSTRACT: A 76-year-old man, who had been treated with interferon-α(IFN-α) for hepatitis C, was diagnosed with multiple hepatocellular carcinomas (HCC; S7/8, S8, S5, S2) with right hepatic vein tumor thrombus (Vv2). He initially underwent transcatheter arterial chemoembolization(TACE). One month after TACE, the hepatic vein tumor thrombi extended into the inferior vena cava(Vv3). No distant metastasis was observed, and his liver function was well-preserved. Therefore, we performed a posterior segmentectomy, partial hepatectomy(S8, S5, S2), inferior vena cava tumor thrombus excision, and cholecystectomy. Four months after the operation, intrahepatic recurrences were detected, and these lesions were controlled via TACE. Four years and 2 months after the initial treatment, the patient survived and presently, is in a good condition. This case suggested that long-term survival is possible by surgery and repeated TACE in case of good liver function by a sustained virologic response (SVR) via treatment with IFN-α for hepatitis C virus.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):1819-21. -
Article: [A case of advanced multiple hepatocellular carcinomas in both lobes that achieved long-term survival after repeated transcatheter arterial chemoembolization and surgical resection].
[show abstract] [hide abstract]
ABSTRACT: A 73-year-old man with advanced multiple hepatocellular carcinoma(HCC) in both lobes(S2, S3, S4, S8, and S1) was admitted to our hospital. Abdominal computed tomography revealed neither vascular invasion nor distant metastasis. Because 3 attempts of transcatheter arterial chemoembolization (TACE) resulted in successful control of the tumors in the right lobe, a left hepatic lobectomy was performed. Although postoperative recurrences were observed, they were controllable by repeated TACE, and the patient remains in a relatively good general condition 3 years and 8 months since the operation.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):1837-9. -
Article: [A case of advanced hepatocellular carcinoma with tumor thrombosis in the main trunk of the portal vein successfully treated by multidisciplinary therapies].
[show abstract] [hide abstract]
ABSTRACT: We report a case of advanced hepatocellular carcinoma(HCC) with tumor thrombosis in the main trunk of the portal vein successfully treated by multidisciplinary therapies. This case is that of a 61-year-old man with loss of appetite and weight loss. The abdominal computed tomography revealed an early enhanced and late wash-out lesion in the right hepatic lobe and tumor thrombosis in the major trunk of the portal vein. We diagnosed advanced HCC related to chronic hepatitis C [T4 (Vp4) N0M0, Stage IVA] and performed extended right lobectomy and extraction of the tumor thrombosis. The patient then underwent hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α therapy as an adjuvant therapy. Two years have passed since these therapies were performed with no recurrence of the disease. We expected that the patient would achieve long-term survival. Therefore, we administered IFN/ribavirin (RBV) therapy for chronic hepatitis C for 48 weeks. The patient is still alive, 44 months after the initial treatment. This case suggests that some patients with advanced HCC and a tumor thrombosis can achieve long-term survival by multidisciplinary therapies, including IFN-α/5-FU combination therapy.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):1867-9. -
Article: [A case of hepatocellular carcinoma treated by transcatheter arterial chemoembolization and hepatectomy after subtotal stomach preserving pancreaticoduodenectomy for duodenal cancer].
[show abstract] [hide abstract]
ABSTRACT: Treatments for hepatocellular carcinoma(HCC) including surgical resection, transcatheter arterial chemoembolization (TACE), percutaneous local therapy, and systemic chemotherapy are decided upon according to tumor progression and liver function. However, it is difficult to choose a treatment after biliary tract reconstruction. Here we report a case of successful treatment for HCC and its recurrence where there had also been subtotal stomach preserving pancreaticoduodenectomy(SSPPD) for duodenal cancer. A 65-year-old female patient who had undergone SSPPD for duodenal cancer was found to have HCC in segment 8 (S8) 12 months later. Three months after super selective TACE, S8 partial resection was performed approaching through right thoracotomy and laparotomy. 2 years after the first hepatectomy, HCC was found to have reoccurred in S7/8 and S8. Right hepatic lobectomy was then performed without blocking the hepatic hilum. Liver resection was carried out with the aim of achieving A-P point. In this case then, several radical treatments have been completed without any biliary complication.Gan to kagaku ryoho. Cancer & chemotherapy 11/2012; 39(12):1988-90. -
Article: [Esophageal cancer].
Nippon rinsho. Japanese journal of clinical medicine 11/2012; 70 Suppl 8:434-7.
Top co-authors
Top Journals
Institutions
-
2013
-
Gunma University
- Graduate School of Medicine
Maebashi-shi, Gunma-ken, Japan -
Kansai Rosai Hospital
Itami, Hyogo-ken, Japan
-
-
1970–2013
-
Kyushu University
- • Division of Surgery
- • Medical Institute of Bioregulation - MIB Hospital
- • Faculty of Medical Sciences
Fukuoka-shi, Fukuoka-ken, Japan
-
-
2012
-
National Defense Medical College
Tokorozawa, Saitama-ken, Japan -
Osaka National Hospital
Ōsaka-shi, Osaka-fu, Japan
-
-
2008–2012
-
Osaka University
- • Gastroenterological Surgery
- • Department of Surgery
Ōsaka-shi, Osaka-fu, Japan
-
-
2009–2011
-
Osaka City University
- • Department of Gastroenterological Surgery
- • Graduate School of Medicine
Ōsaka-shi, Osaka-fu, Japan -
The Ohio State University
- Department of Molecular Virology, Immunology and Medical Genetics
Columbus, OH, USA -
The University of Tokushima
- Department of Surgery
Tokushima-shi, Tokushima-ken, Japan
-
-
2003–2011
-
Teikyo University
- • Department of Surgery
- • Department of Medicine
Tokyo, Tokyo-to, Japan
-
-
2010
-
National and Kapodistrian University of Athens
- Department of Surgery
Athens, Attiki, Greece -
Kitasato University
Tokyo, Tokyo-to, Japan
-
-
2004–2008
-
Jichi Medical University
- Center for Molecular Medicine
Tochigi, Tochigi-ken, Japan
-
-
2003–2008
-
Johns Hopkins University
- Department of Otolaryngology - Head and Neck Surgery
Baltimore, MD, USA
-
-
2007
-
Kagoshima University
- Digestive Surgery II
Kagoshima-shi, Kagoshima-ken, Japan -
University of Ryukyus
- Department of Radiology
Okinawa, Okinawa-ken, Japan
-
-
2005–2006
-
Matsuyama Red Cross Hospital
Matsuyama-shi, Ehime, Japan
-
-
2002–2005
-
Thomas Jefferson University
- Kimmel Cancer Center
Philadelphia, PA, USA -
National Hospital Organization Kyushu Cancer Center
Fukuoka-shi, Fukuoka-ken, Japan
-
